
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Evofosfamide,Balstilimab,Zalifrelimab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ImmunoGenesis Doses First Patient in IMGS-101 Combo Trial for Solid Tumors
Details : IMGS-101 (evofosfamide) is a DNA inhibitor, which is being evaluated for the treatment of rmetastatic castration-resistant prostate cancer, pancreatic, & HPV(-) head & neck tumors.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
March 06, 2025
Lead Product(s) : Evofosfamide,Balstilimab,Zalifrelimab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Evofosfamide
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : University Health Network, Toronto
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Evofosfamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 20, 2025
Lead Product(s) : Evofosfamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : University Health Network, Toronto
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Evofosfamide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Agenus
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
Details : Evofosfamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
January 20, 2025
Lead Product(s) : Evofosfamide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Agenus
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IMGS-501
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : PolyPid
Deal Size : Undisclosed
Deal Type : Collaboration
PolyPid Collaborates with ImmunoGenesis On PLEX Tech for Cancer Immunotherapy
Details : The collaboration aims to address the challenges of IMGS-501. These potent STING agonists are Being evaluated for the treatment of neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 11, 2024
Lead Product(s) : IMGS-501
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : PolyPid
Deal Size : Undisclosed
Deal Type : Collaboration

Details : IMGS-001 is the first dual-specific PD-L1/PD-L2 antibody with cytotoxic function designed to treat cold, immune-excluded tumors, which are resistant to existing immunotherapy.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 28, 2023

Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
Details : IMGS-001 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 28, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IMGS-001
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Cancer Focus Fund
Deal Size : $4.5 million
Deal Type : Funding
Details : The funding will be used to support the Phase 1a/1b clinical trial of ImmunoGenesis' lead candidate, IMGS-001, a dual-specific PD-L1/PD-L2 antibody designed to treat immune-excluded tumors, which are resistant to existing immunotherapy.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
June 27, 2023
Lead Product(s) : IMGS-001
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Cancer Focus Fund
Deal Size : $4.5 million
Deal Type : Funding

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IMGS-001
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IMGS-001, a PD-L1/PD-L2 dual-specific inhibitor with cytotoxic effector function. As first molecule to target PD-L2 in addition to PD-L1, has to shut down entire PD-1 pathway, providing superior blockade compared to other PD-1 or PD-L1 inhibitors.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 03, 2022
Lead Product(s) : IMGS-001
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IMGS-001
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : As the first molecule to target PD-L2 in addition to PD-L1, IMGS-001 has the potential to shut down the entire PD-1 pathway, potentially providing superior blockade compared to other PD-1 or PD-L1 inhibitors.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 15, 2021
Lead Product(s) : IMGS-001
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IMGS-001
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IMGS-001 dual-specific PD‑L1/PD‑L2 antibody designed with effector function to kill the immunosuppressive cells in the tumor microenvironment, re-envisions the starting point for cold tumor treatment.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 03, 2021
Lead Product(s) : IMGS-001
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
